Dendritic cells (DC) are potent antigen-presenting cells derived from CD34 bone marrow stem cells. They undergo a series of maturational steps that allow them to stimulate primary T cell responses. Several cytokines are known to contribute to this process. In this study murine DC maturing from bone marrow progenitors under the influence of granulocyte macrophage colony stimulating factor and tumour necrosis factor-α were found to produce IL-12 as measured by ELISA and by flow cytometry to detect intracellular cytokine. Administration of additional IL-12 from day 3 to 7 of culture altered the function and phenotype of DC; enhanced stimulation of T cell proliferation by DC in allogeneic mixed leukocyte reactions was associated with an increase in the surface expression of CD80 on DC. These effects were dose dependent, and were consistently seen with IL-12 at 25 ng/ml and were less marked with IL-12 at 50 ng/ml. These results show that IL-12 is both produced by DC and can increase their stimulatory capacity. The findings suggest that there may be an autocrine effect of IL-12 on DC maturation and function.
Introduction
Bone marrow-derived dendritic cells (DC) are specialized to acquire and process antigens in peripheral tissues. They transport antigen via the afferent lymphatics to lymph nodes, and mature and up-regulate histocompatibility antigens and co-stimulatory molecules such as CD40, CD80 and CD86. In the lymph nodes, DC have less capacity to process antigen but possess the unique ability to activate naive T cells. DC are also efficient stimulators of secondary T cell immune responses (1) .
IL-12 is a heterodimeric cytokine composed of covalently linked p35 and p40 subunits encoded on two separate genes (2) . The p35 mRNA is constitutively expressed by a variety of cell types, whereas p40 expression is correlated with the production of bioactive p70 by antigen-presenting cells (3) . IL-12 is secreted in three main forms, i.e. the p70 heterodimer, p40 homodimers and p40 monomers. The function of the p40 moieties is not yet established in vivo. However, p70 enhances the proliferation and cytolytic activity of NK cells and T cells, and stimulates IFN-γ production by these cells. DC produce IL-12 which promotes the development of CD4 T h 1 cells from naive T cells (4) (5) (6) . CD40 ligation on DC enhances both their Correspondence to: S. C. Knight Transmitting editor: M. Feldmann Received 13 June 1997, accepted 12 February 1998 maturation and stimulatory capacity in the mixed lymphocyte reaction (MLR) and induces the production of IL-12 in these cells (7) (8) (9) . Since cytokines can amplify the antigen-presenting function of DC, it is possible that IL-12 could play a direct role in this process. The aims of this study were (i) to see if bone marrowderived DC produce IL-12 at different time points during maturation, and (ii) whether IL-12 administration during DC maturation altered cell numbers, phenotype and function.
Materials

Mice
Specific pathogen-free female BALB/c and CBA mice, 6-10 weeks old, were obtained from Northwick Park Institute for Medical Research.
Media and reagents for cell culture
The culture medium (CM) was RPMI 1640 (Dutch modification; Sigma, Poole, UK) supplemented with 10% FCS (Gibco, Paisley, UK), 100 U Penicillin (Gibco), 100 µg/ml streptomycin (Gibco), 2 mM glutamine (ICN Flow, Irvine, UK), 2 mercaptoethanol 10 -5 M (Sigma). Wash medium was identical to the CM but contained bicarbonate-buffered RPMI 1640 instead of the Dutch modification. Granulocyte macrophage colony stimulating factor (GM-CSF) and tumour necrosis factor (TNF)-α (R & D Systems, Oxford, UK) were used at concentrations of 100 and 50 U/ml respectively. IL-12 was a generous gift from Dr M. Gately (Roche Discovery, Nutley, NJ) and was used at 10-50 ng/ml. DC DC were derived from bone marrow precursors as previously described (10) . Briefly, bone marrow was obtained from the femura and tibiae of BALB/c mice. Mononuclear cells were isolated by centrifuging on Lympholyte M (Cedarlane, Hornby, Ontario, Canada). The interface cells were collected, washed and suspended in CM at a concentration of 10 6 cells/ml, and GM-CSF and TNF-α were added. After a 2-4 day incubation the non-adherent cells were centrifuged at 600 g over metrizamide (Nyegaard, Oslo, Norway; 13.7% w/v) to collect the low-density cell population (LDC) in which DC are found. The LDC were resuspended in CM at a cell concentration of 5-10ϫ10 5 cells/ml supplemented with GM-CSF and TNF-α. IL-12 at a concentration from 10-50 ng/ml was then added to the cultures. The medium was changed every 2-3 days and IL-12 together with the other two cytokines were replenished over the next 5 days. After a total of 10-14 days of culture the non-adherent cell population was again centrifuged over a metrizamide gradient, and the LDC washed and suspended in CM. DC numbers were estimated by light microscopy and Trypan blue was used to estimate cell viability. Normal cell viability was 95-100%.
Flow cytometry
The DC were labelled with directly conjugated FITC mAb: mouse I-A d (clone AMS 32.1, IgG2b), mouse H-2D d (clone 34-2-12, IgG2a), hamster anti-mouse CD11c (clone Hl3, hamster IgG), hamster anti-mouse CD54 (clone 3E2, hamster IgG) and rat anti-mouse CD11a (clone C71/16, rat IgG2a). Biotinylated mAb employed were: rat anti-mouse CD40 (clone 3/23, rat IgG2a), rat anti-mouse CD80 (clone 1G10, rat IgG2a), rat anti-mouse CD86 (GL1, IgG2a), rat anti-mouse CD8 (clone ABC, rat IgG2a), hamster anti-mouse CD95 (clone Jo2, hamster IgG) and rat anti-mouse IL-12 (clone C17.15, rat IgG2a). The FITC-conjugated antibodies were purchased from PharMingen (San Diego, CA). The biotinylated IL-12 antibody was obtained from Genzyme (Cambridge, MA) and the other biotin antibodies were obtained from PharMingen. Avidin-FITC and streptavidin-phycoerythirn (PE) (Becton Dickinson, Mountain View, CA) were used to label the biotinylated antibodies.
Twenty percent FCS in FACScan buffer was used to prevent non-specific antibody binding. FITC-conjugated and biotinylated mAb were added to the LDC and the samples were left on ice for 30 min. The cells were then washed in FACScan buffer and avidin-FITC was added. After 20 min these samples were washed and 50 µl of 1% paraformaldehyde added for overnight fixation. Fluorescence profiles were generated on a FACScan flow cytometer (Becton Dickinson). Histogram and density plots were produced by the CellQuest (version 1.0) software package. Viable DC were selected after gating on forward and side scatter with dead cells excluded by propidium iodide staining. The cells which were selected in the gate set around the DC cluster expressed high levels of MHC class II, and were stained by murine markers for DC such as NLDC-145, 33D1 and CD11c as previously described (10) . Several antigens were not detected including CD19 (B cells), CD3ε (T cells) and CD115 (macrophages). Ninety percent of the selected cells expressed the murine-specific DC marker NLDC-145. The user parameters set for experiments involving control and IL-12-treated DC were as follows: FSC linear 5.67, SSC log 242 and FL1 log 460.
Intracellular flow cytometry
Monensin at a concentration of 1.5 mM was added to 5-10ϫ10 5 LDC to ensure intracellular cytokine retention. The LDC/monensin preparation was incubated for 6 h at 37°C. The cells were then washed twice in FACScan buffer containing 20% FCS. Cytoperm A (Serotec, Oxford, UK) was added, the cells kept at room temperature for 15 minutes for fixing and then washed again in FACScan buffer with 20% FCS. Cells were then exposed to permeabilizing agent, Cytoperm B (Serotec), at room temperature for 15 min. The cells were then double labelled at room temperature for the p40 subunit of IL-12 (rat anti-mouse IgG2a; Genzyme) and murine DCspecific markers NLDC-145 (cell line rat IgG2a) and 33D1 (cell line rat IgG2b). The fluorescent cytokine profiles were generated on the FACScan flow cytometer as described above. The user parameters for these experiments were FSC linear 5.67, SSC log 242, FL1 log 440, FL2 log 475, and compensation FL1-FL2 0.6 and FL2-FL1 29.5.
Lymphocyte proliferation assays
Lymphocyte proliferation assays were performed in 20 µl hanging drop cultures on inverted Terasaki plates (11) . CBA lymph nodes were pressed through a wire gauge in medium, washed once and used as responder cells for the BALB/cderived bone marrow DC. On day 3 the cultures were pulsed with 1 µg/ml [ 3 H]thymidine with a sp. act. of 2 Ci/mM (Amersham International, Amersham, UK) for 2 h and then transferred by blotting on to filter discs. The thymidine uptake into proliferating cells was measured in the acid-insoluble fraction on the filter discs in a liquid scintillation counter (Canberra Packard 2000 CA Tri-Carb). This technique gives values that are lower than usual in the 200 µl culture systems, but they reflect accurately the DNA synthesis occurring in these cultures. Data points for each experiment shown represent the mean c.p.m. of triplicate cultures. ANOVA and Student's t-test were used to identify significant effects.
Cytokine measurement IL-12 p70, IL-12 p40, IFN-γ and IL-4 levels were determined by the Intertest solid-phase ELISA kit (Genzyme). Microtiter plates were coated with specific antibodies to capture the cytokine of interest in cell culture supernatants. A second layer antibody was then added. The detection of bound cytokine was achieved using a horseradish peroxidase-conjugated antibody and a colour substrate. Cytokine concentrations were determined with a standard curve derived from known amounts of the relevant cytokine using absorbance readings at 450 nm on a spectrophotometer. There was no interference from p40 in the culture supernatants with the p70 heterodimer. The lower limits of detection for IL-12 were 10 pg/ml for p40 and 5 pg/ml for p70 and the other cytokines.
Results
DC derived from bone marrow preparations secrete IL-12
The presence of IL-12 in supernatants from maturing LDC (10 6 cells) was assessed on day 5 and 8 of culture. IL-12 p40 was found in excess of IL-12 p70 as previously described (6) . The values on day 5 were 120 pg/ml of IL-12 p40 and 20 pg/ml of IL-12 p70. Three days later the amounts of IL-12 p40 and IL-12 p70 had increased to 150 and 24 pg/ml respectively. Similar values for IL-12 were found on repeat experiments. There were no lymphocytes observed in these cultures on light microscopy, which was confirmed on flow cytometry using the T and B cell markers CD3ε and CD19. IFN-γ and IL-4 and IL-10 were not detected in culture supernatants at these time points.
Flow cytometry was used to detect intracellular cytokine production by DC derived from bone marrow precursors. IL-12 p40 was identified in cells which express DC markers (Fig.  1) . A higher proportion of the cells labelled with NLDC than 33D1 as previously described (10) . Almost all the cells producing IL-12 were positive for NLDC and most labelled with 33D1. Eighteen percent of the NLDC-labelled cells and 38% of the 33D1 positive cells were positive for IL-12 p40. Non-specific intracellular binding by the p40 antibody was excluded by showing that IL-12 p70 in excess inhibited intracellular p40 labelling and there was no labelling for IL-12 p40 in the absence of monensin (Fig. 1) . In addition, an isotype antibody (rat anti-mouse IgG2a) was also used as a negative control for IL-12 p40 (data not shown).
IL-12-treated DC exhibit differences in cell surface phenotype and function IL-12 administration did not alter the proportion or numbers of DC derived from bone marrow progenitors as assessed by light microscopy and flow cytometry (data not shown); there was no evidence for any toxic effects of IL-12 at the highest dose. The effect of IL-12 administration at 10, 25 and 50 ng/ ml on the surface phenotype of DC after 10-14 days of culture was examined by flow cytometry. A most striking finding was that 25 ng/ml of IL-12 up-regulated cell surface expression of CD80 on DC. The geometric mean fluorescence intensity of the control DC was significantly higher following IL-12 treatment with 25 ng/ml, e.g. 39.1 compared with 59.9 (Fig. 2) . The influence of 50 ng/ml of IL-12 on CD80 expression on DC was more variable; in some experiments (three out of 10) CD80 expression was also increased (data not shown). There were no reproducible differences in CD80 expression with the lowest dose of IL-12 (10 ng/ml) and mean fluorescence from labelling with a number of other antibodies showed no reproducible differences with any dose of IL-12 (Fig. 2) .
DC treated with IL-12 at 25 ng/ml stimulated higher levels of T cell proliferation than untreated cells (Fig. 3) . DC treated with 50 ng/ml usually did not increase T cell proliferation in the MLR (seven out of 10 experiments), although in the three Fig. 1 . Flow cytometry to measure intracellular IL-12 in DC was performed using double labelling with a biotinylated IL-12 p40 antibody and NLDC or 33D1 as markers for DC as indicated on the axes. Controls for IL-12 p40 labelling were DC incubated with excess IL-12 p70 and cells prepared in the absence of monensin which both showed little labelling, and the results are presented for the cells labelled with NLDC. The percentage of the total cell population that was positive for both markers is indicated. experiments where CD80 expression was elevated there was an increase in the stimulatory capacity of these cells. Results from one experiment where IL-12 treatment at 25 and 50 ng/ ml both increased expression of CD80 T cell proliferation are shown in Fig. 3(B) . The effect of IL-12 dosimetry is indicated as even in this experiment IL-12 treatment at 50 ng/ml was less effective than IL-12 at 25 ng/ml in T cell stimulation with 1000 DC. IL-12 treatment at 10 ng/ml was associated with a reduction in T cell proliferation in the MLR proliferation but this did not reach statistical significance (Fig. 3B) .
Discussion
IL-12 administration at 25 ng/ml to maturing LDC increased the surface expression of CD80 which was associated with an increase in stimulation of T cell proliferation by DC in the MLR. This work also confirms the finding that IL-12 can be secreted by DC in cultures of LDC developing from bone marrow cells (6) . The results raise the concept that IL-12 produced by the DC themselves could influence their maturation; slight variability in the level of endogenously (25) and 50 (50) ng/ml. Similar responses were observed with lower lymph node cell concentrations. The mean fluorescence for CD80 labelling of DC used in this lymphocyte proliferation assay was control, 52.8; IL-12, 10 ng/ml, 32.5; IL-12, 25 ng/ml, 96.5; and IL-12, 50 ng/ml, 72.9.
produced IL-12 might contribute to the greater variability in the effects of higher doses of added IL-12.
There is conflicting data on whether maturing bone marrow DC secrete IL-12 independently of T cell contact. Heufler and colleagues detected IL-12 p40 and p70 in supernatants of bone marrow-derived DC, whereas Winzler and her associates only detected bioactive IL-12 after antigen presentation to T cells (6, 12) . One reason for this discrepancy may well lie in the methods used to generate DC from bone marrow progenitors as DC in this and the Heufler study were more mature than the cells used by Winzler; the ability of DC to produce IL-12 may be proportional to the maturational stage of these cells. This current study shows that IL-12 administration in vitro can influence the maturation and immunostimulatory function of DC independently of T cell contact.
IL-12 is likely to act directly on DC since there were few contaminating cells. In addition, DC are the principal stimulatory cells in the MLR and macrophages show little or no activity in this lymphocyte proliferation assay supporting the evidence of an effect directly on DC (13, 14) . Some of the differences in T cell proliferation observed with the highest doses of IL-12 may again reflect underlying variation in endogenous IL-12 production by DC in different cultures. In addition to any autocrine effects of IL-12 on DC function, the amount of IL-12 that these cells produce may influence the magnitude of T cell proliferation observed in MLR. The mechanisms by which exogenous and endogenous IL-12 may interact to enhance the antigen-presenting capacity of DC remains to be determined.
This work adds IL-12 to the growing numbers of cytokines that can influence antigen presentation by DC. Short-term culture with GM-CSF enhances the stimulatory capacity of skin DC in the MLR (15, 16) . TNF-α enhances the maturation and allostimulatory capacity of DC in long-term murine bone marrow cultures (12) . IL-1α administration has been shown to enhance T cell proliferation in the MLR by spleen, thymus and skin DC (15, 17, 18) . Since IL-12 is produced by DC, it may have an autocrine effect on DC maturation and function in the MLR; this contrasts with IL-1α, which is neither produced by DC nor detected in allogeneic MLR (19, 20) .
Two previous studies had suggested that IL-12 may influence DC antigen-presenting function to T cells, although neither provided any experimental evidence for this. Using BALB/c mice transgenic for V α 11 and V β 3 as a model to examine the development of T h 1 cells it was proposed that IL-12 and IFN-γ could provide a stimulus to antigen-presenting cells to promote IFN-γ secretion by CD4 lymphocytes (21) . Secondly, Enk and colleagues proposed that IL-12 release from human keratinocytes after exposure to allergen could modify antigen presentation by Langerhan cells during primary immune responses in the skin (22) .
Changes in cell surface expression of CD80 are known to influence T cell stimulation by DC. Administration of GM-CSF in vitro to Langerhans cells and other tissue DC increases their ability to stimulate T cell proliferation in allogeneic MLR via CD80 up-regulation (23) . On the other hand, IL-10 can inhibit antigen presentation by Langerhans cells to CD4 T h 1 lymphocytes in BALB/c mice by suppressing their CD80 expression (24) . One possible explanation for the increase in T cell proliferation by IL-12-treated DC is that T h 1 cells are dependent on CD80 for their continued stimulation, as it has been shown that CD80 synergizes with IL-12 to produce IL-2 receptor in murine T h 1 clones (25) . It needs to be established how IL-12 treatment increases the expression of CD80 on DC. Whether IL-12 acts directly on DC via its receptor and Jak-STAT family of transcription molecules or indirectly through the secretion of IFN-γ and TNF-α remains to be determined.
The action of IL-12 on DC function may partially explain its mechanism of action in the treatment of infectious diseases and cancer as well as its role in the induction of organspecific autoimmune diseases. Addition of IL-12 to peripheral blood mononuclear cells obtained from HIV-infected individuals restores the proliferative responses by T cells to a number of different stimuli (26) . As DC infection by HIV can lead to reduced T cell proliferation, it has been proposed that IL-12 may be acting on DC to restore their function in this disease (27) . The possibility that IL-12 can influence antigen presentation by DC was also suggested by two papers which showed that IL-12 treatment in vitro can enhance the ability of DC to induce anti-tumour activity in vivo (28, 29) . IL-12 has also been implicated in the development of autoimmune joint and central nervous system disease (30) . Substitution of Mycobacterium tuberculosis by IL-12 can induce severe arthritis in DBA/1 mice injected with Freund's incomplete adjuvant and type II collagen, suggesting that IL-12 is acting on antigen-presenting cells (31) . Increased expression of IL-12 p40 and CD80 has been described in neuronal plaques of patients with multiple sclerosis, which again suggests that IL-12 may also be acting on antigen-presenting cells in addition to T cells in this disease (32) . The amount of endogenous IL-12 production by DC may have contributed to the effects observed with IL-12 in these studies. Localized production of IL-12 by DC may have either additive or synergistic effects on the systemic administration of IL-12. This could be an important contributor to the outcome of IL-12 therapy in infectious diseases and cancer, and susceptibility to autoimmune diseases.
IL-12 has complex effects on haematopoesis. In vitro administration of IL-12 directly increases the numbers of CD34 bone marrow stem cells and their myeloid progeny in synergy with other growth factors such as stem cell factor (SCF) or IL-3 (33) . IL-12 in vivo decreases peripheral blood counts and bone marrow cellularity largely via IFN-γ induction (34) . In this in vitro study IL-12 had no significant effects on DC numbers derived from bone marrow progenitors. The differences between this work and other in vitro studies may be that IL-12 shows little synergy with GM-CSF in promoting haematopoesis. Further studies examining IL-12 administration in combination with SCF are needed to determine if this cytokine can alter in vitro DC yields from bone marrow-derived precursors.
In conclusion, this study demonstrates that bone marrowderived DC secrete IL-12 p40 and p70, and that IL-12 administration can alter their phenotype and function. The effect of IL-12 on antigen presentation of DC could be used to enhance the effectiveness of vaccines, and could also underlie some of its therapeutic action in the treatment of infectious diseases and cancer.
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